Fatty Acid Synthesis Inhibitor Development Service for Cancer Immunotherapy
The Importance of Fatty Acid Synthesis Inhibitor Development
Lipid metabolism, specifically fatty acid synthesis, is a fundamental cellular process that transforms nutrients into essential components for constructing cell membranes, storing energy reserves, and generating signaling molecules crucial for cellular communication. Altered lipid metabolism is an important metabolic phenotype of cancer cells, and numerous cancer cells rely on the de novo fatty acid synthesis pathway to synthesize membranes and signaling molecules for their rapid proliferation. Therefore, blocking fatty acid synthesis to reduce the level of fatty acid can effectively inhibit the growth and proliferation of cancer cells.
Fig.1 The BCL-2 family controls FASN as well as the cell death decision circuitry.1
Our Fatty Acid Synthesis Inhibitor Development Service for Cancer Immunotherapy
Leveraging industrial-leading expertise and experience, Creative Biolabs globally offers a comprehensive fatty acid synthesis inhibitor development service for cancer immunotherapy. Our service can provide great conveniences for customers on target screening, inhibitor structure design, inhibitor development, tests for efficiency and safety in vitro and in vivo, and even clinical prediction.
Specifically, we provide alternative development strategies and a series of hot targets to choose from for customers' projects. Simultaneously, our state-of-the-art instruments and technologies greatly enhance our capacity to serve your fatty acid synthesis inhibitor development projects. In addition, we also deliver well-developed cancer models to help you examine the inhibitors. Of course, we have confidence in constructing desirable models by your multiple uses. Throughout the process, our scientists will solve problems and optimize the development schemes promptly to ensure high-quality results are delivered for every customer in a short turnaround.
Alternative Strategies for Fatty Acid Synthesis Inhibitor Development
-
Targeting Fatty Acid Synthase
Inhibitors of enzymes have minimal impact on non-cancer cells. Therefore, a variety of synthetic enzymes can be potential drug targets in the process of fatty acid synthesis.
-
Suppressing Fatty Acid Synthesis Genes
Fatty acid synthesis is largely controlled by sterol regulatory element-binding protein 1 (SREBP-1), a significant transcriptional regulator. Under normal conditions, one of its isoforms, SREBP-1c, triggers the process of biosynthesis of fatty acids via response genes. Thus, inhibition of SREBP-1 in cancer cells reduces the expression of fatty acid synthesis genes and can prevent cancer cell proliferation.
Hot Targets Available at Creative Biolabs
Here we provide several hot targets to design for global customers' fatty acid synthesis inhibitor development projects:
Fig.2 Hot targets.
Features of Our Fatty Acid Synthesis Inhibitor Development Service for Cancer Immunotherapy
-
Accelerated development and optimized experiments.
-
Reduce time to market and cut expenses.
-
Identify novel molecules quickly and reduce development delays.
-
One-stop comprehensive customized service.
Frequently Asked Question
Q1: What happens if fatty acid synthase is inhibited?
A1: Evidence suggests that many cancers, but not all, have a lipogenic character. This is quite common in breast and prostate malignancies. On the other side, FAS is primarily responsible for this phenotype. Furthermore, the information presented above suggests that blocking FAS either delays proliferation and development or triggers apoptosis.
For more details about our fatty acid synthesis inhibitor development service for cancer immunotherapy, please don't hesitate to contact us.
Reference
-
Schroeder, Barbara, et al. "Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells." Cell Death & Disease 12.11 (2021): 977.
For Research Use Only | Not For Clinical Use
Download our brochure